Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea
Singapore-based firm last valued at US$827m; does not say how much it is raising in IPO
Singapore
SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).
Earlier on Friday, BT reported that Prestige Biopharma's Singapore-registered entity had been been fully acquired by the Korea Securities Depository (KSD), as shown in Dec 8 regulatory data on intelligence platform VentureCap Insights.
TRENDING NOW
If Europe goes to war, the fallout will be felt in East Asia
Indonesia stocks suffer worst plunge in nearly 30 years as MSCI proposes standalone status
Keppel seeks US$1 billion for Vietnam investments as it joins country’s international financial centre
Philippines’ FDI slowdown exposes uneven investment prospects across S-E Asia
